Literature DB >> 8383649

The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP).

T Ohmori1, T Morikage, Y Sugimoto, Y Fujiwara, K Kasahara, K Nishio, S Ohta, Y Sasaki, T Takahashi, N Saijo.   

Abstract

A cisplatin-resistant non-small cell lung cancer cell line, PC-14/CDDP, was established from PC-14 by stepwise escalation of CDDP concentrations in vitro. PC-14/CDDP cells were 11.4-fold more resistant to CDDP compared with PC-14 cells. This resistant cell line was cross-resistant to platinum analogues, such as carboplatin (CBDCA) (x 3.5), cis-diammine(glycolate-O,O')platinum(II) (254-S) (x 5.6) and cis-dichloro(ethylenediammine)platinum(II) (cis-DEP) (x 4.2). On the other hand, relative resistance value to ormaplatin was only 1.4-fold. To elucidate the mechanism(s) of CDDP resistance and of its circumvention by ormaplatin, we investigated the characteristics of this cell line. Total sulfhydryl content was slightly elevated in PC-14/CDDP cells compared with PC-14 cells. There was no significant difference in the DNA repair ability between the two cell lines. Cellular accumulations of CDDP, CBDCA, 254-S, and cis-DEP in PC-14/CDDP cells were markedly decreased to 23%, 27%, 29%, and 32% of those in PC-14 cells, respectively. However, the accumulation of ormaplatin in PC-14/CDDP was almost the same as that in PC-14. To elucidate the mechanisms of uptake of these platinum analogs in the cells, we studied the effects of ouabain, an Na+,K(+)-ATPase inhibitor, on cellular drug uptake in both cell lines. Preincubation with 300 nM ouabain for 1 h inhibited approximately 60% of CDDP accumulation in PC-14. However ouabain preincubation at any concentration up to 300 nM did not affect CDDP accumulation in PC-14/CDDP. The accumulation of ormaplatin was not inhibited by ouabain in either of the cell lines. These data suggest that the mechanism of the uptake of ormaplatin is different from that of CDDP, and that ormaplatin exerts a cytotoxic effect in CDDP-resistant cells which have defective cisplatin accumulation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8383649      PMCID: PMC5919029          DOI: 10.1111/j.1349-7006.1993.tb02788.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


cis‐diamminedichloroplatinum(II) (cisplatin) trans‐diamminedichloroplatinum(II) cis‐diammine(1, 1‐cyclobutane)dicarboxylatopiatinum(II) (carboplatin) tetrachloro‐(d, 1‐trans)‐1,2‐diaminocyclohexaneplatinum(IV) 1‐trans)‐1,2 ‐ diaminocyclohexaneplatinum (II) cis‐dichloro(ethylenediammine)platinum(II) cis ‐diammine(glycolato‐O, O′)platinum(II) phosphate‐buffered saline DNA‐interstrand cross‐links glutathione drug concentration that inhibits cell growth by 50%
  40 in total

1.  Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent.

Authors:  J Sedlak; R H Lindsay
Journal:  Anal Biochem       Date:  1968-10-24       Impact factor: 3.365

2.  In vivo biochemical indices of nephrotoxicity of platinum analogs tetraplatin, CHIP, and cisplatin in the Fischer 344 rat.

Authors:  M A Smith; J H Smith; C L Litterst; M P Copley; J Uozumi; M R Boyd
Journal:  Fundam Appl Toxicol       Date:  1988-01

3.  Na+-dependent and -independent transport of uridine and its phosphorylation in mouse spleen cells.

Authors:  P G Plagemann; C Woffendin
Journal:  Biochim Biophys Acta       Date:  1989-06-06

Review 4.  Drugs five years later. Cisplatin.

Authors:  P J Loehrer; L H Einhorn
Journal:  Ann Intern Med       Date:  1984-05       Impact factor: 25.391

5.  Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.

Authors:  B C Behrens; T C Hamilton; H Masuda; K R Grotzinger; J Whang-Peng; K G Louie; T Knutsen; W M McKoy; R C Young; R F Ozols
Journal:  Cancer Res       Date:  1987-01-15       Impact factor: 12.701

6.  Characterization of acquired resistance to cis-diamminedichloroplatinum (II) in BE human colon carcinoma cells.

Authors:  R J Fram; B A Woda; J M Wilson; N Robichaud
Journal:  Cancer Res       Date:  1990-01-01       Impact factor: 12.701

7.  Differential uptake of cis-diamminedichloroplatinum (II) by sensitive and resistant murine L1210 leukemia cells.

Authors:  W R Waud
Journal:  Cancer Res       Date:  1987-12-15       Impact factor: 12.701

8.  Hyperthermic potentiation of cis-diamminedichloroplatinum(II) cytotoxicity in Chinese hamster ovary cells resistant to the drug.

Authors:  K E Wallner; M W DeGregorio; G C Li
Journal:  Cancer Res       Date:  1986-12       Impact factor: 12.701

9.  cis-diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines.

Authors:  P J Kuppen; H Schuitemaker; L J van 't Veer; E A de Bruijn; A T van Oosterom; P I Schrier
Journal:  Cancer Res       Date:  1988-06-15       Impact factor: 12.701

10.  Determinants of drug response in a cisplatin-resistant human lung cancer cell line.

Authors:  Y Fujiwara; Y Sugimoto; K Kasahara; M Bungo; M Yamakido; K D Tew; N Saijo
Journal:  Jpn J Cancer Res       Date:  1990-05
View more
  14 in total

1.  Contribution of intracellular ATP to cisplatin resistance of tumor cells.

Authors:  Verena Schneider; Michaela L Krieger; Gerd Bendas; Ulrich Jaehde; Ganna V Kalayda
Journal:  J Biol Inorg Chem       Date:  2012-11-25       Impact factor: 3.358

2.  Predicting chemotherapeutic response to small-cell lung cancer of platinum compounds by thallium-201 single-photon emission computerized tomography.

Authors:  Y Tokuchi; H Isobe; H Takekawa; T Hanada; T Ishida; S Ogura; K Itoh; M Furudate; K Saito; Y Kawakami
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

3.  In vivo screening models of cisplatin-resistant human lung cancer cell lines using SCID mice.

Authors:  Y Heike; M Takahashi; T Ohira; H Arioka; Y Funayama; K Nishio; H Ogasawara; N Saijo
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

4.  Impaired hydrolysis of cisplatin derivatives to aquated species prevents energy-dependent uptake in GLC4 cells resistant to cisplatin.

Authors:  Elene Pereira-Maia; Arlette Garnier-Suillerot
Journal:  J Biol Inorg Chem       Date:  2003-05-17       Impact factor: 3.358

5.  Contributions of microRNA dysregulation to cisplatin resistance in adenocarcinoma cells.

Authors:  Lynn M Pouliot; Ding-Wu Shen; Toshihiro Suzuki; Matthew D Hall; Michael M Gottesman
Journal:  Exp Cell Res       Date:  2012-11-05       Impact factor: 3.905

6.  Anti-tumour activities of a new benzo[c]phenanthridine agent, 2,3-(methylenedioxy)-5-methyl-7-hydroxy-8-methoxybenzo[c]phena nthridini um hydrogensulphate dihydrate (NK109), against several drug-resistant human tumour cell lines.

Authors:  F Kanzawa; K Nishio; T Ishida; M Fukuda; H Kurokawa; H Fukumoto; Y Nomoto; K Fukuoka; K Bojanowski; N Saijo
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  Ormaplatin resistance is associated with decreased accumulation of its platinum (II) analogue, dichloro(D,L-trans)1,2-diaminocyclohexaneplatinum (II).

Authors:  D Rischin; V Ling
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

8.  Cisplatin-functionalized silica nanoparticles for cancer chemotherapy.

Authors:  Chandrababu Rejeeth; Tapas C Nag; Soundarapandian Kannan
Journal:  Cancer Nanotechnol       Date:  2013-07-20

9.  The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer.

Authors:  Yu Fujita; Shigehiro Yagishita; Keitaro Hagiwara; Yusuke Yoshioka; Nobuyoshi Kosaka; Fumitaka Takeshita; Tomohiro Fujiwara; Koji Tsuta; Hiroshi Nokihara; Tomohide Tamura; Hisao Asamura; Makoto Kawaishi; Kazuyoshi Kuwano; Takahiro Ochiya
Journal:  Mol Ther       Date:  2015-01-19       Impact factor: 11.454

10.  In vitro antitumor activity of TAS-103, a novel quinoline derivative that targets topoisomerases I and II.

Authors:  Y Aoyagi; T Kobunai; T Utsugi; T Oh-hara; Y Yamada
Journal:  Jpn J Cancer Res       Date:  1999-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.